Polycystic ovary syndrome and abnormal glucose tolerance

Medical Journal of Australia

Volumn 187, Issue 6, 2007, Pages 324-325

  Teede, Helena J ^a,b   Stuckey, Bronwyn G A ^c  

^a Southern Health   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GLUCOSE; INSULIN; METFORMIN;

AUSTRALIA; CALORIC RESTRICTION; DIABETES MELLITUS; DISEASE ASSOCIATION; ECONOMIC EVALUATION; EDITORIAL; HEALTH CARE COST; HUMAN; HYPERANDROGENISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; OBESITY; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PREVALENCE; SCREENING TEST; UNITED STATES; FEMALE; GLUCOSE TOLERANCE TEST; METABOLISM; NOTE;

FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; POLYCYSTIC OVARY SYNDROME;

EID: 35348829695     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2007.tb01271.x     Document Type: Editorial

References (13)

1. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006; 12: 324-332.
2. Azziz R, Carmina E, Dewailly D, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society Guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245.
3. Teede H, Zoungas S, Hutchison S, Meyer C. Insulin resistance, metabolic syndrome, diabetes and cardiovascular disease in polycystic ovary syndrome. Endocrine 2006; 30: 45-53.
4. Azziz R, Marin C, Hoq L, et al. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005; 90: 4650-4658.
5. Dabadghao P, Roberts BJ, Wang J, et al. Glucose tolerance abnormalities in Australian women with polycystic ovary syndrome. Med J Aust 2007; 187: 328-331.
6. Twigg SM, Kamp MC, Davis TM, et al. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 2007; 186: 461-465.
7. Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modifications in polycystic ovary syndrome. Trends Endocrinol Metab 2002; 13: 251-257.
8. Clark AM, Thornley B, Tomlinson L, Galletly C. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998; 13: 1502-1505.
9. Knowler W, Barrett-Connor E, Fowler S, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
10. Lord JM, Flight I, Norman R. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327: 951-956.
11. Meyer C, McGrath B, Teede HJ. The effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovarian syndrome. Diabetes Care 2007; 30: 471-478.
12. Palomba S, Orio F, Falbo A, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 4068-4074.
13. Cussons AJ, Stuckey BGA, Walsh JP, et al. Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clin Endocrinol (Oxf) 2005; 62: 289-295.